(1)Endocarditis

A high-dose aminoglycoside (eg, tobramycin 8 mg/kg/d) and an extended-spectrum penicillin (eg,

ticarcillin 18 g/d) or antipseudomonal cephalosporin (eg, cefepime) are used for 6 weeks.
Renal function and aminoglycoside level should be monitored.
Surgical evaluation is required because many patients with right-sided endocarditis require
valvulectomy, especially if the bacteremia is not cleared after 2-6 weeks of antibiotics. For left-
sided disease, early surgery is usually required for those with refractory bacteremia or
hemodynamic instability.

(2)Pneumonia
Most experts recommend starting with 2 antipseudomonal antibiotics and then de-escalating to
monotherapy.
Except in patients with cystic fibrosis, the role of an aerosolized aminoglycoside or ceftazidime is
controversial. Efficacy appears to be greater in patients with cystic fibrosis, in whom aerosolized
aminoglycosides have been shown to assist clinical improvement and symptom abatement.
Deciding when to switch from combination therapy to monotherapy: According to the American
Thoracic Society-Infectious Diseases Society of America guidelines for ventilator-assisted
pneumonia, start with combination therapy that includes a beta-lactam and aminoglycoside for 5
days and de-escalate to monotherapy based on organism culture sensitivity.

(3)Bacteremia
Antibiotic therapy is instituted before a specific diagnosis is made.
Once pseudomonal sepsis is suspected in patients with neutropenia, presumptive therapy is a
combination of an aminoglycoside and a broad-spectrum antipseudomonal penicillin or
cephalosporin. The use of monotherapy ceftazidime, a carbapenem (eg, imipenem-cilastatin,
meropenem), or double beta-lactams in patients who are febrile and neutropenic is still
controversial. Fluoroquinolones provide an alternative for the beta-lactam–sensitive patient, and
the addition of rifampin to the beta-lactam and aminoglycoside combination may improve
bacteriologic cure.
Early appropriate antibiotics and aggressive volume replacement have been shown to improve
outcome in septic shock. Positive-pressure ventilation may be required.

(4)Meningitis
Ceftazidime is the antibiotic of choice because of its high penetration into the subarachnoid space
and the high susceptibility of Pseudomonas to this drug.
Initial therapy in critically ill patients should include an intravenous aminoglycoside. The use of an
intrathecal aminoglycoside should be considered, especially in the setting of treatment failure or
relapse.
In renal failure or in the setting of beta-lactam allergy, aztreonam may be an effective second-line
drug. However, clinical experience is limited, and careful observation is suggested.
Clinical experience with ciprofloxacin and meningitis is limited. Animal models suggest equivalent
efficacy to that of ceftazidime and tobramycin, but, for now, combination therapy is suggested.
Therapy is ordinarily continued for 2 weeks. Duration of therapy is determined by the severity of
disease. Monitoring serial CSF cultures and cell counts may be useful in evaluating response to
treatment.
Undertreatment increases the relapse rate and probably the likelihood of acquired resistance, while
overtreatment increases costs and adverse medication effects. In meningitis, overtreatment is
obviously preferred.
(5)Ear infections
External otitis is treated locally with antibiotics and steroids.
Malignant otitis requires aggressive treatment with 2 antibiotics and surgery.
Duration of treatment is 4-8 weeks, depending on the extent of involvement.

(6)Eye infections
In cases of small superficial ulcers, topical therapy, consisting of an ophthalmic aminoglycoside
solution rather than an ointment, is applied to the affected eye every 30-60 minutes.
An ophthalmic quinolone antibiotic is an alternative. When perforation is imminent, subconjunctival
(or subtenon) administration of antibiotics is preferred.
Management of endophthalmitis is quite complex, requiring aggressive antibiotic therapy
(parenteral, topical, subconjunctival [or subtenon], and, often, intraocular). Vitrectomy may be
required to assist in eyesight preservation.

(7)Urinary tract infections

Parenteral aminoglycosides may remain the antibiotics of choice, although quinolones are often
used.
Tobramycin is preferred to gentamicin in patients with renal dysfunction.
UTI can be treated with a single agent, except in cases of bacteremia and upper tract infections
with abscess formation.
Alternative antibiotics include antipseudomonal penicillins and cephalosporins, carbapenems (eg,
imipenem, meropenem), and aztreonam. Ciprofloxacin continues to be the preferred oral agent.
Duration of therapy is 3-5 days for uncomplicated infections limited to the bladder; 7-10 days for
complicated infections, especially with indwelling catheters; 10 days for urosepsis; and 2-3 weeks
for pyelonephritis. Longer duration of treatment is necessary for those patients with perinephric or
intrarenal abscesses.
GI tract infection treatment includes administration of antibiotics and hydration.
Skin and soft tissue infections
Double antibiotic therapy should be instituted in accordance with the local susceptibility patterns
because burn centers may harbor Pseudomonas strains that are resistant to multiple drugs.
Silver sulfadiazine and sodium piperacillin have been shown to be effective in experimental models
of burn sepsis.
Aggressive surgical debridement is necessary, and avoidance of whirlpool treatments is
suggested.